Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

King Faisal Specialist Hospital & Research Center

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: Cisplatin-Docetaxel ± Trastuzumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00535509

RAC #2061-048

Details and patient eligibility

About

Phase II trial of Neoadjuvant [FEC100]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer

Enrollment: 285 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with locally advanced breast cancer

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)